Oppenheimer Reviews BioCryst Earnings
In a report published Monday, Oppenheimer analysts maintained a Perform rating on BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX), saying that clinical data could drive the stock higher in 2H15.
BioCryst reported its 1Q15 revenue and EPS at $6.8M and ($0.21), as compared to the Oppenheimer estimates of $3.2M and ($0.26), respectively.
In the report Oppenheimer noted the upcoming milestones for BioCryst as:
- Phase 1a PK/PD/safety data from BCX7353 in 3Q15
- Phase 2b data from BCX4161 (OPuS-2 trial) in 4Q15
- Initiation of a Phase 1b proof-of-concept trial of BCX7353 in 4Q15
"We reiterate our Perform rating on BCRX fundamentals, but see opportunity for share price appreciation in 2H15," the analysts said, citing the "large valuation gap" to competitor Dyax Corp. (NASDAQ: DYAX) and "in anticipation of BCX7353 and BCX4161 readouts in 3Q and 4Q15, respectively."
Latest Ratings for BCRX
|Feb 2017||Ladenburg Thalmann||Initiates Coverage On||Buy|
|Dec 2016||JMP Securities||Upgrades||Market Perform||Market Outperform|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.